Affiliation:
1. Department of Pharmacy Practice, Teerthanker Mahaveer College of Pharmacy, Moradabad, Uttar Pradesh, India
2. Department of Pharmacology, Teerthanker Mahaveer Medical College and Research Centre, Moradabad, Uttar Pradesh,
India
Abstract
Abstract:
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a new class of drugs that lower
blood glucose levels while decreasing blood pressure, volume loss, and weight loss. SGLT2
inhibitors were studied to determine their effectiveness in treating cardiovascular disease and
their side effects. Study outcomes related to cardiovascular and metabolic outcomes were examined
in patients on SGLT2 inhibitors by searching PubMed, Embase, Cochrane, and SCOPUS.
Articles related to clinical trials, reviews, and meta-analyses were considered. A review of
SGLT2 inhibitors' mechanisms of action in preventing cardiovascular (CVS) disease progression
was described. We then reviewed the possible effects of SGLT2 inhibitors on CVS dysfunction
development, composition, and stability. In the following, we discussed the impact of SGLT2 inhibitors
on CVD events, such as ischemic strokes and myocardial infarctions, and their role in
treating congestive heart failure and cardiovascular mortality.
Publisher
Bentham Science Publishers Ltd.
Subject
General Health Professions
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献